AIO-Studien gGmbH

7 trials 1 recruiting Academic / non-commercial Merged from 2 name variants

Filter these 7 trials by condition, phase, country and more.

Open in Search →

7 Registered trials

1 Recruiting

3 Completed trials

1 Countries active

12 Unique IMPs

100% Results reported

Phase III

Phase II

Phase I/II

Phase III: 1 Phase II: 5 Phase I/II: 1

Oversight events:

1 temporary halt across 1 trial

View oversight register →

100%

3 of 3 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).

View full Transparency Scoreboard →

Top indications

Non-small cell lung cancer 2 Colorectal cancer 2 Non-small cell lung cancer stage IIIB 1 Prostate cancer stage IV 1 Adenocarcinoma of colon 1 Colorectal cancer metastatic 1 Hormone-dependent prostate cancer 1 Non-small cell lung cancer stage IIIA 1 Prostate cancer metastatic 1 Small cell lung cancer recurrent 1 Non-small cell lung cancer stage III 1 Prostate cancer 1

Top IMPs

ATEZOLIZUMAB 2 BMS-986365 1 METHADONE HYDROCHLORIDE 1 MYCOBATERIUM OBUENSE, STRAIN NCTC 13365, HEAT-KILLED 1 OSIMERTINIB 1 SACITUZUMAB GOVITECAN 1 TARLATAMAB 1 ZIMBERELIMAB 1

All trials

7 total

Randomized trial of standard chemotherapy alone or combined with atezolizumab as adjuvant therapy for patients with stage III colon cancer a… Pending

2024-517269-18-00 Phase III 1 country ATEZOLIZUMAB
A multicenter phase II study of neoadjuvant sacituzumab govitecan plus zimberelimab followed by adjuvant zimberelimab with or without sacitu… Pending

2024-517561-16-00 Phase II 1 country SACITUZUMAB GOVITECAN; ZIMBERELIMAB
Phase 2 trial of ARPI to AR-degrader (BMS-986365) switch for suboptimal PSA-response in mCSPC (eARly-SWITCH). Pending

2025-523672-23-00 Phase II 1 country BMS-986365
A single-arm phase II-study to confirm efficacy and feasibility of tarlatamab treatment in patients with extensive stage small-cell lung can… Recruiting

2025-522437-65-00 Phase II 1 country TARLATAMAB
Perioperative/Adjuvant atezolizumab in patients with MSI-high or MMRdeficient stage II high risk or stage III colorectal cancer ineligible f… Ended

2024-515224-37-00 Phase II 1 country ATEZOLIZUMAB; MYCOBATERIUM OBUENSE, STRAIN NCTC 13365, HEAT-KILLED
Radiation during Osimertinib Treatment: a Safety and Efficacy Cohort Study (ROSE) Ended

2022-503028-29-01 Phase II 1 country OSIMERTINIB
A phase I/II trial of D,L-MEthadone and mFOLFOX6 in treatment of advanced colorectal cancer (MEFOX) Ended

2024-519509-37-00 Phase I/II 1 country METHADONE HYDROCHLORIDE

Showing 1–7 of 7 trials

← All sponsors A–Z